These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 31793511)

  • 1.
    Katoch P; Bisht GS; Shrivastava R
    Int J Mycobacteriol; 2019; 8(4):390-396. PubMed ID: 31793511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ribosomal maturation factor (RimP) is essential for survival of nontuberculous mycobacteria
    Poonam ; Yennamalli RM; Bisht GS; Shrivastava R
    3 Biotech; 2019 Apr; 9(4):127. PubMed ID: 30863706
    [No Abstract]   [Full Text] [Related]  

  • 3. A transposon insertion mutant of Mycobacterium fortuitum attenuated in virulence and persistence in a murine infection model that is complemented by Rv3291c of Mycobacterium tuberculosis.
    Parti RP; Shrivastava R; Srivastava S; Subramanian AR; Roy R; Srivastava BS; Srivastava R
    Microb Pathog; 2008; 45(5-6):370-6. PubMed ID: 18930129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo activity of thiophene-containing trisubstituted methanes against acute and persistent infection of non-tubercular Mycobacterium fortuitum in a murine infection model.
    Kashyap VK; Gupta RK; Shrivastava R; Srivastava BS; Srivastava R; Parai MK; Singh P; Bera S; Panda G
    J Antimicrob Chemother; 2012 May; 67(5):1188-97. PubMed ID: 22311937
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Random insertion transposon mutagenesis of Mycobacterium fortuitum identified mutant defective in biofilm formation.
    Katoch P; Gupta K; Yennamalli RM; Vashistt J; Bisht GS; Shrivastava R
    Biochem Biophys Res Commun; 2020 Jan; 521(4):991-996. PubMed ID: 31727369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Knockdown of the Type-II Fatty acid synthase gene
    Sharma A; Vashistt J; Shrivastava R
    Int J Mycobacteriol; 2022; 11(2):159-166. PubMed ID: 35775548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transcriptional analysis of Mycobacterium fortuitum cultures upon hydrogen peroxide treatment using the novel standard rrnA-P1.
    Núñez MC; Menéndez MC; Rebollo MJ; García MJ
    BMC Microbiol; 2008 Jun; 8():100. PubMed ID: 18565220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel streptomycin resistance gene from Mycobacterium fortuitum.
    Ramón-García S; Otal I; Martín C; Gómez-Lus R; Aínsa JA
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3920-2. PubMed ID: 16954315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular basis of intrinsic macrolide resistance in clinical isolates of Mycobacterium fortuitum.
    Nash KA; Zhang Y; Brown-Elliott BA; Wallace RJ
    J Antimicrob Chemother; 2005 Feb; 55(2):170-7. PubMed ID: 15590712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Control of Mycobacterium fortuitum and Mycobacterium intracellulare infections with respect to distinct granuloma formations in livers of BALB/c mice.
    Silva TR; Petersen AL; Santos Tde A; Almeida TF; Freitas LA; Veras PS
    Mem Inst Oswaldo Cruz; 2010 Aug; 105(5):642-8. PubMed ID: 20835610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Murine infection model for Mycobacterium fortuitum.
    Parti RP; Srivastava S; Gachhui R; Srivastava KK; Srivastava R
    Microbes Infect; 2005 Mar; 7(3):349-55. PubMed ID: 15777648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial Susceptibility Testing and Molecular Characterization of Mycobacterium fortuitum Isolates in China.
    Zheng HW; Pang Y; He GX; Song YY; Zhao YL
    Biomed Environ Sci; 2017 May; 30(5):376-379. PubMed ID: 28549494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taxonomic variation in the Mycobacterium fortuitum third biovariant complex: description of Mycobacterium boenickei sp. nov., Mycobacterium houstonense sp. nov., Mycobacterium neworleansense sp. nov. and Mycobacterium brisbanense sp. nov. and recognition of Mycobacterium porcinum from human clinical isolates.
    Schinsky MF; Morey RE; Steigerwalt AG; Douglas MP; Wilson RW; Floyd MM; Butler WR; Daneshvar MI; Brown-Elliott BA; Wallace RJ; McNeil MM; Brenner DJ; Brown JM
    Int J Syst Evol Microbiol; 2004 Sep; 54(Pt 5):1653-1667. PubMed ID: 15388725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. katGI and katGII encode two different catalases-peroxidases in Mycobacterium fortuitum.
    Menéndez MC; Ainsa JA; Martín C; García MJ
    J Bacteriol; 1997 Nov; 179(22):6880-6. PubMed ID: 9371430
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of subinhibitory concentrations of ciprofloxacin on Mycobacterium fortuitum mutation rates.
    Gillespie SH; Basu S; Dickens AL; O'Sullivan DM; McHugh TD
    J Antimicrob Chemother; 2005 Aug; 56(2):344-8. PubMed ID: 15956099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete genome sequence of Mycobacterium fortuitum subsp. fortuitum type strain DSM46621.
    Ho YS; Adroub SA; Aleisa F; Mahmood H; Othoum G; Rashid F; Zaher M; Ali S; Bitter W; Pain A; Abdallah AM
    J Bacteriol; 2012 Nov; 194(22):6337-8. PubMed ID: 23105073
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Species Distribution and Macrolide Susceptibility of
    Kim SY; Moon SM; Jhun BW; Kwon OJ; Huh HJ; Lee NY; Lee SH; Shin SJ; Kasperbauer SH; Huitt GA; Daley CL; Koh WJ
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30885902
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and laboratory features of Mycobacterium porcinum.
    Wallace RJ; Brown-Elliott BA; Wilson RW; Mann L; Hall L; Zhang Y; Jost KC; Brown JM; Kabani A; Schinsky MF; Steigerwalt AG; Crist CJ; Roberts GD; Blacklock Z; Tsukamura M; Silcox V; Turenne C
    J Clin Microbiol; 2004 Dec; 42(12):5689-97. PubMed ID: 15583300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of tetracycline resistance mediated by the efflux pump Tap from Mycobacterium fortuitum.
    Ramón-García S; Martín C; Aínsa JA; De Rossi E
    J Antimicrob Chemother; 2006 Feb; 57(2):252-9. PubMed ID: 16373429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of resistant mutants of Mycobacterium chelonae and Mycobacterium fortuitum after exposure to subinhibitory concentrations of clarithromycin and moxifloxacin.
    Rodriguez JC; Garcia-Pachon E; Flores E; Escribano I; Ruiz M; Royo G
    J Chemother; 2007 Oct; 19(5):599-601. PubMed ID: 18073162
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.